Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1301 to 1350 of 1867 results for do not do

  1. What are the long-term outcomes, both psychotic and nonpsychotic, for children and young people with attenuated or transient psychotic symptoms suggestive of a developing psychosis, and can the criteria for 'at risk states' be refined to better predict those who will and those who will not go on to develop psychosis?

    most at risk, and reduce the numbers of those thought to be 'at risk' who do not go on to later develop psychosis. Source guidance...

    Research recommendation
    Published
    9 June 2015

  2. Evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    page. Any explanatory notes(if applicable) Clinicians wanting to do prostatic urethral temporary implant insertion for lower urinary...

    Research recommendation
    Published
    30 September 2022

  3. Evidence on the efficacy and safety of neurostimulation of lumbar muscles for refractory non-specific chronic low back pain is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    page. Any explanatory notes(if applicable) Clinicians wanting to do neurostimulation of lumbar muscles for refractory non-specific...

    Research recommendation
    Published
    30 September 2022

  4. Effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse:- What is the effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse in the UK?

    festivals, would provide prevention data for hard-to-reach groups and those who do not access existing services. Research could also...

    Research recommendation
    Published
    4 May 2017

  5. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

    Medtech innovation briefing
    Published
    10 May 2022

  6. myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)

    NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .

    Medtech innovation briefing
    Published
    1 October 2018

  7. Drug misuse prevention (QS165)

    This quality standard covers the prevention or delay of harmful use of drugs by children, young people and adults most likely to start using drugs, or already experimenting or using drugs occasionally. This includes illegal psychoactive substances, solvents, volatile substances, image- and performance-enhancing drugs, prescription-only medicines and over-the-counter medicines. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    29 March 2018
    View quality statements

    Sections for QS165

  8. Prostate cancer (QS91)

    This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    30 December 2021
    View quality statements

    Sections for QS91

  9. What interventions are effective and cost effective in supporting return to work after recurrent short-term sickness absence in the UK?

    need similar support when returning to work. The recommendations therefore do not distinguish between supporting people returning from...

    Research recommendation
    Published
    10 February 2020

  10. Guide to the methods of technology appraisal 2013 (PMG9)

    This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process

  11. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

    Highly specialised technologies guidance
    Published
    10 January 2024
    View recommendations

    Sections for HST30

  12. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA805

  13. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)

    Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.

    Technology appraisal guidance
    Published
    20 November 2024
    View recommendations

    Sections for TA1018

  14. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

    Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    8 August 2018

    Sections for TA536

  15. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA425

  16. Sorafenib for treating advanced hepatocellular carcinoma (TA474)

    Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

    Technology appraisal guidance
    Published
    6 September 2017
    View recommendations

    Sections for TA474

  17. What components of alcohol education delivery contribute to its effectiveness for children and young people aged 11 to 18 in full-time education, and those with special educational needs and disabilities (SEND) up to the age of 25?

    committee agreed that the spiral curriculum concept is a logical approach to do this. No evidence was identified for alcohol education...

    Research recommendation
    Published
    25 October 2019

  18. How effective and cost effective are education-based alcohol interventions targeted at children and young people aged 11 to 25 with SEND who are thought to be vulnerable to alcohol misuse?

    committee agreed that the spiral curriculum concept is a logical approach to do this. No evidence was identified for alcohol education...

    Research recommendation
    Published
    25 October 2019

  19. How effective are education-based alcohol prevention interventions (universal or targeted) for children and young people aged 11 to 25 with SEND in full-time education?

    committee agreed that the spiral curriculum concept is a logical approach to do this. No evidence was identified for alcohol education...

    Research recommendation
    Published
    25 October 2019

  20. What is the cost effectiveness and safety of non-surgical ablation and stereotactic body radiotherapy compared to resection for people with metastatic colorectal cancer in the lung amenable to local treatment?

    teams that specialise in primary lung disease may not be appropriate as they do not specialise in the management of lung metastases from...

    Research recommendation
    Published
    10 February 2020

  21. What is the most clinically and cost-effective treatment for diverticular disease?

    causes and further investigations in people with persistent symptoms or who do not respond to treatment. How the recommendations might...

    Research recommendation
    Published
    10 February 2020

  22. How effective and cost effective are universal, education-based alcohol interventions for children and young people aged 11 to 25 with SEND?

    committee agreed that the spiral curriculum concept is a logical approach to do this. No evidence was identified for alcohol education...

    Research recommendation
    Published
    25 October 2019

  23. ADXBLADDER for detecting bladder cancer (MIB180)

    NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .

    Medtech innovation briefing
    Published
    12 April 2019

  24. VAAFT for treating anal fistulae (MIB102)

    NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .

    Medtech innovation briefing
    Published
    20 April 2017

  25. Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)

    NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus

    Medtech innovation briefing
    Published
    21 April 2015

  26. The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)

    NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system

    Medtech innovation briefing
    Published
    1 February 2014

  27. Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)

    Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.

    Technology appraisal guidance
    Published
    14 December 2022
    View recommendations

    Sections for TA849

  28. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA461

  29. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.

    Technology appraisal guidance
    Published
    20 November 2019
    View recommendations

    Sections for TA612

  30. Early pregnancy assessment units: A national evaluation of early pregnancy assessment unit service provision should be carried out to identify factors affecting outcomes. Factors should include whether care is provided in a dedicated unit, staffing configuration and opening hours of dedicated services. Outcomes should include both process (service) outcomes and pregnancy-related outcomes. Data collected should be used to analyse the cost effectiveness of early pregnancy assessment units compared with other models of care.

    pregnancy services carrying out more formal follow‑up of women than they might do currently, for the duration of the audit. The...

    Research recommendation
    Published
    17 December 2021

  31. Recommendation 1 Research studies and trials. Who should take action? Research councils, commissioners and funders.

    questionnaire to investigate dietary intake. If validated tools for secondary measures do not exist, a tool to measure the outcome (for...

    Research recommendation
    Published
    9 June 2015

  32. Current evidence on the safety of ultrasound-guided high‑intensity transcutaneous focused ultrasound for symptomatic uterine fibroids shows there are well-recognised complications including skin burns. The evidence on efficacy is limited in quality. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    research. Any explanatory notes(if applicable) Clinicians wishing to do ultrasound-guided high‑intensity transcutaneous focused...

    Research recommendation
    Published
    15 November 2019

  33. Recommendation 4 Weight management programmes. Who should take action? Research councils, commissioners and funders. Researchers and investigators.

    such interventions? - Determine the long-term effectiveness of programmes. Do children and young people who have lost or maintained...

    Research recommendation
    Published
    9 June 2015

  34. Mega Soft Patient Return Electrode for use during monopolar electrosurgery (HTG290)

    Evidence-based recommendations on Mega Soft Patient Return Electrode for use during monopolar electrosurgery.

    HealthTech guidance
    Published
    22 August 2012
    View recommendations

    Sections for HTG290

  35. The evidence for treating an acute migraine attack is adequate but, for treating subsequent attacks, is limited in quality and quantity. So, for treating acute migraine, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page . The evidence for preventing migraine is inadequate in quality. So, for preventing migraine, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page.

    page. Any explanatory notes(if applicable) Clinicians wanting to do transcutaneous electrical stimulation of the supraorbital nerve for...

    Research recommendation
    Published
    7 November 2022

  36. Acute coronary syndromes in adults (QS68)

    This quality standard covers diagnosing and managing acute coronary syndromes in adults (aged 18 and over). Acute coronary syndromes are medical emergencies that include myocardial infarction (heart attack) and unstable angina (unexpected, severe chest pain). It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    18 November 2020
    View quality statements

    Sections for QS68

  37. EpiFix for chronic wounds (MIB139)

    NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .

    Medtech innovation briefing
    Published
    30 January 2018

  38. QuikRead go for C-reactive protein testing in primary care (MIB78)

    NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care

    Medtech innovation briefing
    Published
    14 September 2016

  39. SYNE-COV for predicting COVID-19 outcomes (MIB264)

    NICE has developed a medtech innovation briefing (MIB) on SYNE-COV for predicting COVID-19 outcomes .

    Medtech innovation briefing
    Published
    15 June 2021

  40. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA340

  41. Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)

    Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.

    Technology appraisal guidance
    Published
    27 March 2013
    View recommendations

    Sections for TA276

  42. Referral criteria for people with suspected axial spondyloarthritis:- What are the optimal referral criteria for people with suspected axial spondyloarthritis?

    subset of the data. A UK-specific dataset would provide more relevant data to do this than is currently available from the Dutch CaFaSpA...

    Research recommendation
    Published
    4 May 2017

  43. Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)

    Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).

    HealthTech guidance
    Published
    4 July 2018
    View recommendations

    Sections for HTG476

  44. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

    Evidence-based recommendations on rituximab for the first-line treatment of stage III–IV follicular lymphoma.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA243

  45. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.

    Highly specialised technologies guidance
    Published
    22 May 2024
    View recommendations

    Sections for HST31

  46. Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

    Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

    Technology appraisal guidance
    Published
    27 January 2016
    View recommendations

    Sections for TA380

  47. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

    Technology appraisal guidance
    Published
    4 June 2015
    View recommendations

    Sections for TA341

  48. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA177

  49. Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

    Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600 mutation.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA396

  50. What is the effectiveness, cost effectiveness and acceptability of the whole family approach to carers' assessments?

    health and social care need to work together on carers' assessments, but they do not always have the relevant skills and...

    Research recommendation
    Published
    10 February 2020